Humacyte Enters Credit Facility of Up to $77.5MM with Avenue Capital
Humacyte, a commercial-stage biotechnology platform company, entered into a credit facility with Avenue Venture Opportunities Fund II, a fund of Avenue Capital Group, providing up to $77.5 million in principal amount of new financing. The credit agreement, which has a...
Read moreDetails








